Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 198 for “"Her2"”.
-
Resistance to HER2-targeted therapies in HER2-positive breast cancer
… and human epidermal growth factor receptor 2 (HER2). Historically, HER2-positive breast cancers had a worse survival prognosis than oestrogen or progesterone receptor-positive cancers, but the development of HER2-targeted therapies led to significant survival improvements. Despite this, …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… rates. Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of BC. HER2 overexpression is also observed in other cancers such as gastric/gastroesophageal, ovarian, lung, prostate, bladder, colon and head and neck. HER2-positive BC is characterized by aggressive disease and …
-
Metabolic vulnerability in HER2-positive Breast Cancer
… human epidermal growth factor receptor 2, or HER2, is overexpressed in 20-30% breast cancer patients and is associated with aggressive disease. Therapies targeting HER2, including monoclonal antibodies (trastuzumab and pertuzumab), a small molecule kinase inhibitor (lapatinib) and an …
-
INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY
… human epidermal growth factor receptor-2 (HER2) specifically in breast cancer. Poly (D, L-lactide-co-glycolide) (PLGA) polymer, which is approved by FDA, was used to form nanoparticles (NPs) encapsulating docetaxel (DOC) as chemotherapy. HER2 antibody moieties, either whole IgG (TrAb) or …
-
Interaction Between Brk and Her2 In Breast Cancer
<p><strong>INTERACTION BETWEEN BRK AND HER2 IN BREAST CANCER</strong></p> <p>Midan Ai, Ph.D.</p> <p>Supervisory Professor: Zhen Fan, M.D.</p> <p>Breast tumor kinase (Brk) is a nonreceptor protein-tyrosine kinase that is highly expressed in approximately two thirds of breast cancers but is not …
-
Functionalization and Modification of Naphthaquinone Analogs as HER2 Kinase Inhibitors
<p>HER2 overexpression in breast cancer tumors predicts lower overall survival. Because of the aggressive nature of HER2 tumors and the association with metastatic disease, the HER2 receptor holds great promise as a therapeutic target in metastatic breast cancer. We are developing small molecule …
-
EGFR & HER2 trafficking and signaling dynamics : experimental and modeling studies
EGFR and HER2 expression levels have distinguished themselves as important factors in contributing to various types of cancers including breast and ovarian cancers, but quantitative linkages between receptor expression levels and aberrant cell behaviors are not well understood. The ability to …
-
Studium vlivu N-vázané glykosylace na funkci nanoprotilátky cílící receptor HER2
… buňkách. Jeden z těchto markerů je receptor HER2, jehož exprese je zvýšená například na povrchu nádorových buněk karcinomu prsu. Jako terapeutické protilátky se často používají humanizované monoklonální protilátky, ale používají se i jiné konstrukty, jako jsou bispecifické částice, …
-
Identification and Characterization of Her2/Neu-Transformed Breast Cancer Stem Cells
… stem cells in our model system that mimics Her2-positive subtype of human breast cancer, we cultivated primary tumor cells and grew tumorspheres under non-adherent condition. Cells capable of forming tumorspheres retained ability of self-renewal and capacity for initiating tumors that …
-
Enhertu (Trastuzumab Deruxtecan): Ανασκόπηση της κλινικής ανάπτυξης σε ασθενείς με HER2+ καρκίνο μαστού / Enhertu (Trastuzumab Deruxtecan): A review of clinical development in patients with HER2-positive breast cancer
… Deruxtecan, T-DXd, Enhertu) σε ασθενείς με HER2-θετικό καρκίνο του μαστού, εστιάζοντας στην αποτελεσματικότητα, την ασφάλεια και τον ρόλο της στα σύγχρονα θεραπευτικά σχήματα. Μεθοδολογία: Πραγματοποιήθηκε συστηματική αναζήτηση στη βιβλιογραφία σε βάσεις δεδομένων όπως PubMed, Scopus και …
-
Anti-Insulin Resistance Treatments Suppress Her2+ Breast Cancer Growth Via Altering Metabolism
… treatments are associated with improved HER2<sup>+</sup> breast cancer survival of diabetic women. However, there were no transgenic mouse models to study the correlation and explain the detailed mechanism. We generated a mouse model of HER2<sup>+</sup> breast cancer with DM2 by crossing …
-
Rational design, characterization and in vivo studies of antibody mimics against HER2
<p>Human Epidermal Growth Factor Receptor 2 (HER2) is a cell surface receptor tyrosine kinase and plays a role in the signal pathways leading to cell proliferation and differentiation. Overexpression of HER2 is found in various cancers including breast, ovarian, gastric, colon, and non-small-cell …
-
Targeting the actin cytoskeleton in HER2+ metastatic cancer cells using a macrolide toxin
… of the human epidermal growth factor receptor 2 (HER2) leads to overexpression of the receptor on the cell surface. Previous studies have found that these HER2+ cancers show high rates of progression to metastatic disease. Metastasis is driven by cytoskeletal rearrangements that produce …
-
HER2 and Folate Receptor Targeted Therapy is Enhanced by NK Cell-Activating Cytokines
… that co-administration of IL-12 with an anti-HER2 mAb (4D5) would enhance the FcR dependent immune mechanisms and IFN-gamma production and contribute to its anti-tumor activity. We aimed to elucidate the cell type responsible for this elevated IFN-gamma production and further determine how …
-
Exploring the mechanism of SHP2 and EGFR/HER2 cooperation in breast cancer cell signaling
… of receptor tyrosine kinases like EGFR and HER2. As such, targeting of SHP2 is being recognized as a potentially viable therapeutic option in HER2-positive and triple-negative breast cancers. In this report, I employed molecular and cellular biology techniques to further elucidate the role …
-
Jab1 Negatively Regulates Pten and Promotes Resistance to Trastuzumab In Her2-Positive Breast Cancer
<p>HER2-positive breast cancer, which is characterized by the over-expression of the HER2 onco-protein, accounts for approximately 20% of all breast cancer cases. Trastuzumab (Herceptin), the first targeted therapy approved for HER2-positive disease, potently prevents the activation of signaling …
Page 1 of 10